Comparison · NCT01495481-fbec533d
Dexmedetomidine vs Adenosine: Termination of SVT
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dexmedetomidine vs Adenosine: Termination of SVT. Trial comparisons, record NCT01495481-fbec533d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01495481-fbec533d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.727 | 0.518 | 0.868 | wilson | |
| Risk in group 2 | 0.955 | 0.782 | 0.992 | wilson | |
| Risk difference, group 1 minus group 2 | -0.227 | -0.439 | -0.00432 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.762 | 0.581 | 1 | log | |
| Odds ratio, group 1 over group 2 | 0.127 | 0.0139 | 1.16 | log | |
| Number needed to treat, for one fewer participant with the outcome on Dexmedetomidine than on Adenosine | 4.4 | 2.28 | 232 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dexmedetomidine | Patients will receive dexmedetomidine for the termination of SVT~Dexmedetomidine: Dexmedetomidine 1 mcg/kg, Intravenous push | 16 | 22 | OG000 |
| Group 2 | Adenosine | Patients will receive Adenosine for the termination of SVT~Adenosine: stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful | 21 | 22 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Termination of SVT
- Description
- Number of participants with SVT Termination within 3 minutes of medication administration
- Time frame
- Within 3 minutes
- Population
Source ClinicalTrials.gov
Trial
- Title
- Dexmedetomidine and Adenosine: Therapeutic Use for SVT
- NCT number
- NCT01495481
- Phases
- NA
- Conditions
- Supraventricular Tachycardia
- Interventions
- Dexmedetomidine, Adenosine
- Lead sponsor
- University of Pittsburgh
- Results first posted
- 2017-03-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01495481?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01495481-fbec533d